NCT06348771

Brief Summary

The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice, but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain and inflammation. Given these findings, this study will examine the postprandial effects of meals with 2 levels of saturated fatty acids (SFA) on metabolic endotoxemia, inflammation and satiety, using a randomized cross-over design. The low SFA meal includes peanuts that are high in monounsaturated fatty acids (MUFA) and this will be compared to a high SFA meal. The results of this study have the potential to provide valuable insights into the role of peanuts in promoting health and preventing disease in at-risk older adults.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
17

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2024

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 22, 2024

Completed
3 days until next milestone

Study Start

First participant enrolled

March 25, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 5, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 6, 2025

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

September 29, 2025

Status Verified

January 1, 2025

Enrollment Period

10 months

First QC Date

March 22, 2024

Last Update Submit

September 26, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Concentration of Endotoxin

    serum

    Change over 6 hour MMT

Secondary Outcomes (4)

  • Concentration of Glucose and Insulin

    Change over 6 hour MMT

  • Concentration of Triglyceride

    Change over 6 hour MMT

  • Appetite

    Change over 6 hour MMT

  • Concentration of Inflammatory markers

    Change over 6 hour MMT

Other Outcomes (5)

  • Concentration of zonulin

    Baseline only

  • Lipid Profile

    Baseline only

  • Characterization of the Microbiome

    Baseline only

  • +2 more other outcomes

Study Arms (2)

saturated fatty acids (SFA) meal

ACTIVE COMPARATOR

mixed meal test over 6 hours

Behavioral: monounsaturated fatty acids (MUFA) peanut meal

monounsaturated fatty acids (MUFA) peanut meal

EXPERIMENTAL

mixed meal test over 6 hours

Behavioral: monounsaturated fatty acids (MUFA) peanut meal

Interventions

mixed meal tolerance test and postprandial measurements

Also known as: Saturated fatty acid (SFA) meal
monounsaturated fatty acids (MUFA) peanut mealsaturated fatty acids (SFA) meal

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Older adults across all racial/ethnic groups
  • Older men, and postmenopausal women \> 2 years since last menses.

You may not qualify if:

  • Anemia
  • Diagnosed with, active, or history of liver cirrhosis, chronic or persisting hepatitis
  • Diagnosed with, active, or history of cancer
  • History of gastrointestinal disease or surgical procedure for weight loss.
  • Diagnosed with immune diseases, type 1 or 2 diabetes, pancreatitis, metabolic bone disease or infectious diseases
  • Any surgery in the past 6 months
  • Currently using or have used antibiotics continuously \> 3 days in the past 3 months
  • Regular use of medications for that affect the gastrointestinal tract, cholecystitis, urinary tract infection, significant renal disease, severe organic diseases including coronary heart disease, myocardial infarction, infectious diseases including pulmonary tuberculosis and AIDS
  • Known allergy or intolerance to any ingredients in the meal intervention
  • Recent colonoscopy (within the previous two months)
  • Uncontrolled hypertension or uncontrolled severe hyperlipidemia.
  • Participation in another clinical research trial that may interfere with the results of this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Foran Hall

New Brunswick, New Jersey, 08901, United States

Location

Rutgers University - NJ Inst Food Nutrition & Health

New Brunswick, New Jersey, 08901, United States

Location

MeSH Terms

Conditions

OverweightObesity

Interventions

Fatty Acids, MonounsaturatedFatty AcidsMeals

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Fatty Acids, UnsaturatedLipidsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Sue Shapses, PhD

    Rutgers, the State University of NJ

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No masking but participants are not told which foods in a given meal are higher in one fatty acid or another. 16 will be enrolled as per the sample size calculation for this study.
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Higher SFA meal vs higher MUFA (nut) meal in individuals with overweight and obese
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 22, 2024

First Posted

April 5, 2024

Study Start

March 25, 2024

Primary Completion

January 6, 2025

Study Completion

May 1, 2026

Last Updated

September 29, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Individual participant data that underlie the results and after deidentification will be shared upon request for researchers who provide a methodologically sound proposal (and IRB approved).

Locations